Metastatik Pankreas Kanserli Hastalarda FOLFİRİNOX Rejiminin Etkinlik ve Tolerabilitesi
Yükleniyor...
Tarih
2018
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Amaç: Metastatik pankreas kanseri tedavisinde FOLFİ-RİNOX rejiminin kullanımı hem progresyonsuz sağ kalımıhemde genel sağ kalım süresini uzatmıştır. Türk popülasyonundametastatik pankreas kanserli hastalarda birinciseride FOLFİRİNOX rejimi kullanımının etkinlik ve güvenilirliğiniretrospektif olarak araştırmak istedik.Gereç ve Yöntem: Çalışma retrospektif çok merkezli olarakdizayn edilmiştir. 2012-2016 yılları arasında birinci seriFOLFİRİNOX rejimi ile tedavi edilen metastatik pankreaskanserli hastalar dahil edilmiştir.Bulgular: Çalışmaya 44 metastatik pankreas kanserli hastaalındı. Hastalardan 30’u erkek (%68,2), 14’ü kadındı(%31,8). Hastaların yaş ortalaması 58,7 (34-73) yıldı. Mediantakip süremiz 14 ay idi. Hastaların metastaz bölgelerinebakıldığında %72,7 karaciğere, %18,2 akciğere, %18,2peritona, %4,5 lenf nodlarına ve %4,5 kemiklere metastazyapmıştı. Tedaviye yanıt oranlarına bakıldığında %40,9hastada parsiyel yanıt, %13,6 hastada stabil yanıt, %45,4hastada progresyon mevcuttu. Median progresyonsuz sağkalım süresi 8 ay (%95 CI 4-12) olarak bulundu. Mediangenel sağ kalım süresi 14 ay (%95 CI 10.3-17.7), 6 aylıkgenel sağ kalım %76,2, 12 aylık genel sağ kalım %57,5, 24aylık genel sağ kalım %6 olarak bulundu. Toksisite oranlarınabakıldığında grade 3-4 Nöropeni %36,4 (grade 3%27,3, grade 4 %9,1), grade 3-4 trombositopeni %13,6hastada görüldü. Grade 3-4 anemi %14,6 hastada görüldü.Hematolojik dışı yan etkilerden grade 1-2 ishal %68olmasına rağmen grade 3-4 ishal %4,5 oranında görüldü.Grade 1-2 periferik duysal nöropati %72,7 oranında görülürkengrade 3-4 duysal nöropati tespit edilmedi.Sonuç: Metastatik pankreas kanserinde FOLFİRİNOX rejimikullanılarak 12 ayın üzerine çıkan bir genel sağkalımaulaşılmıştır. Fakat grade 3-4 hematolojik yan etki oranı%49’lara kadar çıkmıştır.
Objective: The use of the FOLFIRINOX regimen in thetreatment of metastatic pancreatic cancer prolonged bothprogression-free survival and overall survival. We wantedto retrospectively investigate the efficacy and safety of firstlineFOLFIRINOX regimen use in patients with metastaticpancreatic cancer in the Turkish population.Material and Methods: The study was designed as retrospectivemulticenter. Patients with metastatic pancreaticcancer treated with the first series FOLFIRINOX regimenbetween the years 2012-2016 were included.Results: Forty-four patients with metastatic pancreaticcancer were included in the study. 30 patients were male(68.2%) and 14 were female (31.8%). The mean age of thepatients was 58.7 (34-73) years. Our median follow-up was14 months. When the metastatic sites of the patients wereexamined, 72.7% had liver, 18.2% lung, 18.2% peritoneal,4.5% lymph nodes and 4.5% bones metastases. There was40.9% partial response, 13.6% stable disease and 45.4%progression disease in the patients. The median progression-free survival time was 8 months (95% CI 4-12). Medianoverall survival time was 14 months (95% CI 10.3-17.7), 6months overall survival was 76.2%, 12 months overall survivalwas 57.5% and 24 months overall survival was 6%.Grade 3-4 neuropeni was found in 36.4% (grade 3, 27.3%,grade 4 9.1%) and grade 3-4 thrombocytopenia was foundin 13.6% of the patients. Grade 3-4 anemia was seen in14.6% of the patients.Grade 3-4 diarrhea was seen in 4.5%of cases, although grade 1-2 diarrhea was 68% with nonhematologicside effects. Grade 1-2 peripheral sensory neuropathywas observed in 72.7% of the cases, whereas grade3-4 sensory neuropathy was not detected.Conclusion: Patients with metastatic pancreatic cancerachieved a overall survival of over 12 months using theFOLFIRINOX regimen. However, grade 3-4 hematologicside-effects were up to 49%.
Objective: The use of the FOLFIRINOX regimen in thetreatment of metastatic pancreatic cancer prolonged bothprogression-free survival and overall survival. We wantedto retrospectively investigate the efficacy and safety of firstlineFOLFIRINOX regimen use in patients with metastaticpancreatic cancer in the Turkish population.Material and Methods: The study was designed as retrospectivemulticenter. Patients with metastatic pancreaticcancer treated with the first series FOLFIRINOX regimenbetween the years 2012-2016 were included.Results: Forty-four patients with metastatic pancreaticcancer were included in the study. 30 patients were male(68.2%) and 14 were female (31.8%). The mean age of thepatients was 58.7 (34-73) years. Our median follow-up was14 months. When the metastatic sites of the patients wereexamined, 72.7% had liver, 18.2% lung, 18.2% peritoneal,4.5% lymph nodes and 4.5% bones metastases. There was40.9% partial response, 13.6% stable disease and 45.4%progression disease in the patients. The median progression-free survival time was 8 months (95% CI 4-12). Medianoverall survival time was 14 months (95% CI 10.3-17.7), 6months overall survival was 76.2%, 12 months overall survivalwas 57.5% and 24 months overall survival was 6%.Grade 3-4 neuropeni was found in 36.4% (grade 3, 27.3%,grade 4 9.1%) and grade 3-4 thrombocytopenia was foundin 13.6% of the patients. Grade 3-4 anemia was seen in14.6% of the patients.Grade 3-4 diarrhea was seen in 4.5%of cases, although grade 1-2 diarrhea was 68% with nonhematologicside effects. Grade 1-2 peripheral sensory neuropathywas observed in 72.7% of the cases, whereas grade3-4 sensory neuropathy was not detected.Conclusion: Patients with metastatic pancreatic cancerachieved a overall survival of over 12 months using theFOLFIRINOX regimen. However, grade 3-4 hematologicside-effects were up to 49%.
Açıklama
Anahtar Kelimeler
Metastatik pankreas kanseri, FOLFİRİNOX, Toksisite, Metastatic pancreas cancer, Toxicity
Kaynak
Okmeydanı Tıp Dergisi
WoS Q Değeri
Scopus Q Değeri
Cilt
34
Sayı
2
Künye
Karaağaç, M., Artaç, M., Geredeli, Ç., Cihan, Ş., Yaşar, N., Sakin, A., Can, O., Koral, L. (2018). Metastatik pankreas kanserli hastalarda Folfirinox rejiminin etkinlik ve tolerabilitesi. Okmeydanı Tıp Dergisi, 34, 2, 76-81.
